Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: Special reference to its inverse relationship with E-cadherin expression

Teiyu Izumi, Yoshinao Oda, Tadashi Hasegawa, Yukihiro Nakanishi, Akira Kawai, Hiroshi Sonobe, Tomonari Takahira, Chikashi Kobayashi, Hidetaka Yamamoto, Sadafumi Tamiya, Setsuo Hirohashi, Yukihide Iwamoto, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dysadherin is a cancer-associated cell membrane glycoprotein, which down-regulates E-cadherin and promotes metastasis. Synovial sarcoma is a very rare mesenchymal tumor that exhibits an epithelial profile. To confirm the diagnosis of synovial sarcoma, we evaluated several immunohistochemical markers, or detected SYT-SSX fusion gene transcript. We studied the clinicopathologic features in 92 synovial sarcoma patients and also assessed the immunohistochemical expression of dysadherin and E-cadherin to examine their possible association with histologic subtype and biologic behavior. Moreover, among 30 patients, for whom frozen materials were available, dysadherin mRNA expression was examined by reverse transcription-polymerase chain reaction and real-time quantitative reverse transcription-polymerase chain reaction analysis. Dysadherin-positive expression was significantly correlated with E-cadherin-reduced expression (P=0.0004). Dysadherin-positive immunostaining was diffusely observed in the membranes of tumor cells in 30/68 (44%) patients with monophasic fibrous type and in 1/2 (50%) patients with poorly differentiated type. However, in biphasic tumors, dysadherin expression in the fibrous component was not diffusely observed, but often sporadically or focally observed [20/22 (91%) patients]. In addition, dysadherin mRNA expression in monophasic fibrous type was significantly higher than in biphasic type (P=0.0079). Synovial sarcoma patients with dysadherin expression survived for a significantly shorter time than those without dysadherin expression (P=0.0006). Patients with combined dysadherin-positive expression and E-cadherin-reduced expression had a significantly worse prognosis than those with other combinations of dysadherin and E-cadherin expression (P=0.0007). SYT-SSX fusion gene transcript was detected in 39 patients. In our series, SYT-SSX fusion type was found to have no correlation with histologic subtype, prognosis, or dysadherin expression. In multivariate analysis, dysadherin immunopositivity (P=0.0411) was an independent adverse prognostic factor, in addition to a high MIB-1 labeling index (≥10%). We conclude that E-cadherin dysfunction by dysadherin is associated with reduced E-cadherin expression and morphologic change from epithelioid to spindle phenotype. Dysadherin expression is considered to be one of the determinants of histologic subtype in synovial sarcoma. Moreover, dysadherin expression is an excellent and independent prognostic indicator.

Original languageEnglish
Pages (from-to)85-94
Number of pages10
JournalAmerican Journal of Surgical Pathology
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

Fingerprint

Synovial Sarcoma
Cadherins
Gene Fusion
Reverse Transcription
Neoplasms
Cell Membrane
Messenger RNA
Membrane Glycoproteins
Real-Time Polymerase Chain Reaction
Down-Regulation
Multivariate Analysis
Neoplasm Metastasis
Phenotype
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma : Special reference to its inverse relationship with E-cadherin expression. / Izumi, Teiyu; Oda, Yoshinao; Hasegawa, Tadashi; Nakanishi, Yukihiro; Kawai, Akira; Sonobe, Hiroshi; Takahira, Tomonari; Kobayashi, Chikashi; Yamamoto, Hidetaka; Tamiya, Sadafumi; Hirohashi, Setsuo; Iwamoto, Yukihide; Tsuneyoshi, Masazumi.

In: American Journal of Surgical Pathology, Vol. 31, No. 1, 01.01.2007, p. 85-94.

Research output: Contribution to journalArticle

Izumi, Teiyu ; Oda, Yoshinao ; Hasegawa, Tadashi ; Nakanishi, Yukihiro ; Kawai, Akira ; Sonobe, Hiroshi ; Takahira, Tomonari ; Kobayashi, Chikashi ; Yamamoto, Hidetaka ; Tamiya, Sadafumi ; Hirohashi, Setsuo ; Iwamoto, Yukihide ; Tsuneyoshi, Masazumi. / Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma : Special reference to its inverse relationship with E-cadherin expression. In: American Journal of Surgical Pathology. 2007 ; Vol. 31, No. 1. pp. 85-94.
@article{59c7f6d92413447e973cd3727d861d1a,
title = "Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: Special reference to its inverse relationship with E-cadherin expression",
abstract = "Dysadherin is a cancer-associated cell membrane glycoprotein, which down-regulates E-cadherin and promotes metastasis. Synovial sarcoma is a very rare mesenchymal tumor that exhibits an epithelial profile. To confirm the diagnosis of synovial sarcoma, we evaluated several immunohistochemical markers, or detected SYT-SSX fusion gene transcript. We studied the clinicopathologic features in 92 synovial sarcoma patients and also assessed the immunohistochemical expression of dysadherin and E-cadherin to examine their possible association with histologic subtype and biologic behavior. Moreover, among 30 patients, for whom frozen materials were available, dysadherin mRNA expression was examined by reverse transcription-polymerase chain reaction and real-time quantitative reverse transcription-polymerase chain reaction analysis. Dysadherin-positive expression was significantly correlated with E-cadherin-reduced expression (P=0.0004). Dysadherin-positive immunostaining was diffusely observed in the membranes of tumor cells in 30/68 (44{\%}) patients with monophasic fibrous type and in 1/2 (50{\%}) patients with poorly differentiated type. However, in biphasic tumors, dysadherin expression in the fibrous component was not diffusely observed, but often sporadically or focally observed [20/22 (91{\%}) patients]. In addition, dysadherin mRNA expression in monophasic fibrous type was significantly higher than in biphasic type (P=0.0079). Synovial sarcoma patients with dysadherin expression survived for a significantly shorter time than those without dysadherin expression (P=0.0006). Patients with combined dysadherin-positive expression and E-cadherin-reduced expression had a significantly worse prognosis than those with other combinations of dysadherin and E-cadherin expression (P=0.0007). SYT-SSX fusion gene transcript was detected in 39 patients. In our series, SYT-SSX fusion type was found to have no correlation with histologic subtype, prognosis, or dysadherin expression. In multivariate analysis, dysadherin immunopositivity (P=0.0411) was an independent adverse prognostic factor, in addition to a high MIB-1 labeling index (≥10{\%}). We conclude that E-cadherin dysfunction by dysadherin is associated with reduced E-cadherin expression and morphologic change from epithelioid to spindle phenotype. Dysadherin expression is considered to be one of the determinants of histologic subtype in synovial sarcoma. Moreover, dysadherin expression is an excellent and independent prognostic indicator.",
author = "Teiyu Izumi and Yoshinao Oda and Tadashi Hasegawa and Yukihiro Nakanishi and Akira Kawai and Hiroshi Sonobe and Tomonari Takahira and Chikashi Kobayashi and Hidetaka Yamamoto and Sadafumi Tamiya and Setsuo Hirohashi and Yukihide Iwamoto and Masazumi Tsuneyoshi",
year = "2007",
month = "1",
day = "1",
doi = "10.1097/01.pas.0000213413.33558.85",
language = "English",
volume = "31",
pages = "85--94",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma

T2 - Special reference to its inverse relationship with E-cadherin expression

AU - Izumi, Teiyu

AU - Oda, Yoshinao

AU - Hasegawa, Tadashi

AU - Nakanishi, Yukihiro

AU - Kawai, Akira

AU - Sonobe, Hiroshi

AU - Takahira, Tomonari

AU - Kobayashi, Chikashi

AU - Yamamoto, Hidetaka

AU - Tamiya, Sadafumi

AU - Hirohashi, Setsuo

AU - Iwamoto, Yukihide

AU - Tsuneyoshi, Masazumi

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Dysadherin is a cancer-associated cell membrane glycoprotein, which down-regulates E-cadherin and promotes metastasis. Synovial sarcoma is a very rare mesenchymal tumor that exhibits an epithelial profile. To confirm the diagnosis of synovial sarcoma, we evaluated several immunohistochemical markers, or detected SYT-SSX fusion gene transcript. We studied the clinicopathologic features in 92 synovial sarcoma patients and also assessed the immunohistochemical expression of dysadherin and E-cadherin to examine their possible association with histologic subtype and biologic behavior. Moreover, among 30 patients, for whom frozen materials were available, dysadherin mRNA expression was examined by reverse transcription-polymerase chain reaction and real-time quantitative reverse transcription-polymerase chain reaction analysis. Dysadherin-positive expression was significantly correlated with E-cadherin-reduced expression (P=0.0004). Dysadherin-positive immunostaining was diffusely observed in the membranes of tumor cells in 30/68 (44%) patients with monophasic fibrous type and in 1/2 (50%) patients with poorly differentiated type. However, in biphasic tumors, dysadherin expression in the fibrous component was not diffusely observed, but often sporadically or focally observed [20/22 (91%) patients]. In addition, dysadherin mRNA expression in monophasic fibrous type was significantly higher than in biphasic type (P=0.0079). Synovial sarcoma patients with dysadherin expression survived for a significantly shorter time than those without dysadherin expression (P=0.0006). Patients with combined dysadherin-positive expression and E-cadherin-reduced expression had a significantly worse prognosis than those with other combinations of dysadherin and E-cadherin expression (P=0.0007). SYT-SSX fusion gene transcript was detected in 39 patients. In our series, SYT-SSX fusion type was found to have no correlation with histologic subtype, prognosis, or dysadherin expression. In multivariate analysis, dysadherin immunopositivity (P=0.0411) was an independent adverse prognostic factor, in addition to a high MIB-1 labeling index (≥10%). We conclude that E-cadherin dysfunction by dysadherin is associated with reduced E-cadherin expression and morphologic change from epithelioid to spindle phenotype. Dysadherin expression is considered to be one of the determinants of histologic subtype in synovial sarcoma. Moreover, dysadherin expression is an excellent and independent prognostic indicator.

AB - Dysadherin is a cancer-associated cell membrane glycoprotein, which down-regulates E-cadherin and promotes metastasis. Synovial sarcoma is a very rare mesenchymal tumor that exhibits an epithelial profile. To confirm the diagnosis of synovial sarcoma, we evaluated several immunohistochemical markers, or detected SYT-SSX fusion gene transcript. We studied the clinicopathologic features in 92 synovial sarcoma patients and also assessed the immunohistochemical expression of dysadherin and E-cadherin to examine their possible association with histologic subtype and biologic behavior. Moreover, among 30 patients, for whom frozen materials were available, dysadherin mRNA expression was examined by reverse transcription-polymerase chain reaction and real-time quantitative reverse transcription-polymerase chain reaction analysis. Dysadherin-positive expression was significantly correlated with E-cadherin-reduced expression (P=0.0004). Dysadherin-positive immunostaining was diffusely observed in the membranes of tumor cells in 30/68 (44%) patients with monophasic fibrous type and in 1/2 (50%) patients with poorly differentiated type. However, in biphasic tumors, dysadherin expression in the fibrous component was not diffusely observed, but often sporadically or focally observed [20/22 (91%) patients]. In addition, dysadherin mRNA expression in monophasic fibrous type was significantly higher than in biphasic type (P=0.0079). Synovial sarcoma patients with dysadherin expression survived for a significantly shorter time than those without dysadherin expression (P=0.0006). Patients with combined dysadherin-positive expression and E-cadherin-reduced expression had a significantly worse prognosis than those with other combinations of dysadherin and E-cadherin expression (P=0.0007). SYT-SSX fusion gene transcript was detected in 39 patients. In our series, SYT-SSX fusion type was found to have no correlation with histologic subtype, prognosis, or dysadherin expression. In multivariate analysis, dysadherin immunopositivity (P=0.0411) was an independent adverse prognostic factor, in addition to a high MIB-1 labeling index (≥10%). We conclude that E-cadherin dysfunction by dysadherin is associated with reduced E-cadherin expression and morphologic change from epithelioid to spindle phenotype. Dysadherin expression is considered to be one of the determinants of histologic subtype in synovial sarcoma. Moreover, dysadherin expression is an excellent and independent prognostic indicator.

UR - http://www.scopus.com/inward/record.url?scp=33845943967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845943967&partnerID=8YFLogxK

U2 - 10.1097/01.pas.0000213413.33558.85

DO - 10.1097/01.pas.0000213413.33558.85

M3 - Article

C2 - 17197923

AN - SCOPUS:33845943967

VL - 31

SP - 85

EP - 94

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 1

ER -